(21.05.2025) The biotechnology industry generated stable revenues of 7.2 billion Swiss francs in 2024, while fundraising and investments rose sharply (+25%) to 2.5 billion, according to the Swiss Biotech Report 2025.
Research and development (R&D) reached 2.6 billion francs, an increase of 8% compared to the previous year. With 833 million francs raised (+39%), privately held companies made a significant contribution to the overall rise in investment in the Swiss biotech sector in 2024. The largest fundraising rounds in this category came from Alentis Therapeutics (163 million francs) and SixPeaks Bio (102 million francs).
Despite continued challenging conditions for publicly listed companies, CRISP Therapeutics secured 247 million francs in funding for its clinical trials.
Swiss biotech firms also forged notable international partnerships. Vaud-based AC Immune teamed up with Japan’s Takeda, Basel-based Idorsia partnered with U.S.-based Viatris, and Haya Therapeutics, also from Vaud, joined forces with Lilly in the United States. The 2024 financial year also saw major mergers and acquisitions. Notably, Johnson & Johnson acquired Yellow Jersey – a subsidiary of Zurich-based Numab – for 1.25 billion dollars, while Lonza purchased Roche’s Vacaville site in the U.S. for 1.2 billion dollars.
Drug regulatory agencies, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Swissmedic, also approved a record number of new therapeutic products in 2024. These approvals significantly boosted sales in the Swiss biotech sector.
Last modification 21.05.2025
